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Long non-coding RNAOur previous studies have shown that the 3′ end of metastasis associated lung adenocarcinoma transcript 1
(MALAT1) is involved in colorectal cancer (CRC) cell proliferation and migration/invasion in vitro. The role and
mechanism of MALAT1 in CRC metastasis in vivo, however, remain largely unknown. In the present study, we
found that MALAT1 was up-regulated in human primary CRC tissues with lymph node metastasis. Overexpres-
sion ofMALAT1 via RNA activation promoted CRC cell proliferation, invasion andmigration in vitro, and stimulat-
ed tumor growth andmetastasis inmice in vivo. Conversely, knockdown ofMALAT1 inhibited CRC tumor growth
andmetastasis. MALAT1 regulated at least 243 genes in CRC cells in a genome-wide expression proﬁling. Among
these genes, PRKA kinase anchor protein 9 (AKAP-9) was signiﬁcantly up-regulated at both mRNA and protein
levels. AKAP-9 was highly expressed in CRC cells with metastatic potential and human primary CRC tissues
with lymph node metastasis, but not in normal cells or tissues. Importantly, knockdown of AKAP-9 blocked
MALAT1-mediated CRC cell proliferation, migration and invasion. These data indicate thatMALAT1may promote
CRC tumor development via its target protein AKAP-9.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Long non-coding RNAs (lncRNA) are non-protein coding transcripts
longer than 200 nucleotides [1–3]. Emerging evidences show that
lncRNAs are associated with a spectrum of biological processes such as
gene regulation on transcriptional and post-transcriptional levels [4,5],
chromatin modiﬁcation and epigenetics, alternative splicing, protein
activity modulation, and protein localization, etc. Dysregulation of
lncRNAs is also an important feature of many complex human diseases,
including Alzheimer's disease [6] ischemic diseases [7], heart disease [8]
and cancer [9,10]. In fact, lncRNAs have been recognized as a hallmark of
the onset and development of various tumors or tumor suppressor
pathways [11,12].
The metastasis associated lung adenocarcinoma transcript 1
(MALAT1) is an 8.1 kb long noncoding RNA transcribed from the
nuclear-enriched transcript 2 (NEAT2). As a highly abundant nucleus-enocarcinoma transcript 1; CRC,
LncRNA, long non-coding RNA;
n;H&E, hematoxylin–eosin
y, Nanfang Hospital, Southern
20 61648223.
mu.edu.cn (Z.-G. Li).restricted RNA, MALAT1 can modulate the activity of serine/arginine
(SR) splicing factor including its pre-mRNA splicing and mRNA export
[13,14]. MALAT1 is found to enhance the proliferation and invasion of
nasopharyngeal carcinoma cell line CNE-1 [15]. Numerous in vivo stud-
ies have shown that transient overexpression of MALAT1 enhances
tumor formation of gastric cancer [16], gallbladder cancer [17], and
lung cancer [18] in nude mice while depletion of MALAT1 in tumor
cells reduces tumorigenicity [19]. In fact, MALAT1 is considered as an
independent prognosticmarker and a potential target for antimetastatic
therapy in lung cancer [19]. Although these studies strongly indicate
thatMALAT1plays an important role in carcinogenesis, themechanisms
whereby MALAT1 induces colorectal carcinoma growth or metastasis
remains largely unknown.
Colorectal cancer (CRC) is the third leading cause of cancer death
worldwide. Metastasis is the major cause of mortality in patients with
colorectal tumor [20]. However, little is known about the key mecha-
nisms and factors underlying the complex process of CRC tumor in-
vasion and metastasis. Our previous studies show that a MALAT1
fragment at the 3′ end of the LncRNA plays a pivotal role in the prolifer-
ation, migration and invasion of CRC cells in vitro [14,21]. However, the
role and mechanism of MALAT1 in CRC tumor growth and metastasis
in vivo remain to be determined. In the present study, we found that
MALAT1 is closely associatedwith themetastasis of human CRC. Byma-
nipulating MALAT1 expression in CRC cells or tumor cubes that were
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MALAT1 in tumorigenesis and metastasis in vivo. Most importantly,
we have identiﬁed anchor protein 9 (AKAP-9) as a downstream target
that is responsible for MALAT1 function in CRC cell proliferation and
migration/invasion.
2. Materials and methods
2.1. Cell culture and tissue specimens
Human colorectal cancer cell lines HCT116, SW480, SW620, LoVo,
CaCo-2, HT-29, Lst174-t, and COLO205 were obtained from the Cell
Bank of the Chinese Academy of Sciences (Shanghai, China). The M5
cells with enhanced metastatic capability were isolated by an in vivo
selection of SW480 cells. The stably-transduced cell lines SW480-
RNAi-MALAT1 (RNA interference), SW480-RNAa-MALAT1 (RNA activa-
tion), and SW480-control (scramble control) were established by
lentiviral vector (pGCSIL-GFP, GeneChem, ShangHai, China) trans-
duction of SW480 cells. All CRC cells were cultured in RPMI 1640 medi-
um (Gibco, USA) supplemented with 10% fetal bovine serum (FBS)
(Hyclone, USA) and 100 U/ml penicillin/streptomycin (Life Tech-
nologies, USA) and incubated in a humidiﬁed chamber with 5% CO2 at
37 °C. The tumor samples were obtained from 27 patients, paired with
normal tissues (10 cm away from the colorectal tumor). Nine of them
had metastatic lymph-nodes. Patient's consent and approval from the
Ethics Committee of Southern Medical University were obtained before
use of these clinical materials for research, and the clinical information
about the patients is listed in Supplemental Table S1. In each selected
case, pathological diagnosis was performed in the Department of Pa-
thology of Nanfang Hospital, and all patients had undergone elective
surgery for CRC in Nanfang Hospital during March to April in 2009.
2.2. RNA isolation and MALAT1 expression analysis
Total RNA was extracted with TRIzol Reagent (Invitrogen). First
strand cDNA was synthesized with the PrimeScript™ RT Kit (Takara
Biotechnology Co, Japan). MALAT1 expression was detected by both
semi-quantitative polymerase chain reaction (PCR) and quantitative
qPCR using PrimeScript™ PCR Master Mix (Takara Biotechnology Co)
and an ABI 7500 Real-Time PCR system. GAPDHwas used as an internal
control that is comparablewith cyclophilin control. The assaywas run in
triplicate for each sample.
2.3. Plasmid and lentivirus preparation
MALAT1 was knocked down with RNA interference (RNAi) or
overexpressed by RNA activation (RNAa) targeting on mRNA or pro-
moter region of MALAT1 gene. Stealth RNAiTM negative control with
medium GC content was purchased from Invitrogen. The promoter of
human MALAT1 was analyzed for promoter motifs and high GC
domains by using Promoter Scan Searcher and CpG Island Searcher
software. RNAi cDNA and the promoter-dsDNA sequence was cloned
into the pGCSIL-GFP lentiviral expression vector according to the
manufacturer's instruction.
2.4. Cell proliferation assay and cell cycle analysis
Cells were seeded in 96-well plates at 0.8–1 × 103 per well. Cell pro-
liferation was evaluated using Cell Counting Kit-8 (CCK-8, Dojindo,
USA) according to the manufacturer's instructions. Brieﬂy, 10 μl of
CCK-8 solution was added to culture medium, and incubated for 2 h.
The absorbance at 450nmwavelengthwasdeterminedwith a reference
wavelength of 570 nm. For cell-cycle analysis, cells were plated in 6-
well plates at 5 × 105 per well. The cell-cycle distribution was analyzed
by propidium iodide (Sigma-Aldrich) staining and ﬂow cytometry. All
experiments were performed in triplicates.2.5. Colony formation assay
Cells were plated in 6-well plates at 1-2 × 102 per well and main-
tained in RPMI1640 containing 10% FBS. After 12–14 days, the cells
were washed twice with PBS, ﬁxed with methanol and stained with
Giemsa solution. The number of colonies containing ≥50 cells was
counted under a microscope. All these experiments were performed in
triplicates.
2.6. Wound healing assay
Cells were cultured in standard conditions until 80–90% conﬂuence
and treated with mitomycin C (10 μg/ml) during the wound healing
assay. The cell migration was assessed by measuring the movement of
cells into the acellular area created by a sterile insert. Thewound closure
was observed after 48 h.
2.7. Invasion assay
For invasion assays, matrigel-coated chambers (BD Biosciences,
USA) containing 8 μm pores were used for the assays. Brieﬂy, 2 × 105
cells were seeded into the upper chambers (coated in Matrigel) in
serum-free medium. The lower chamber of the transwell was ﬁlled
with culture media containing 10% FBS as a chemo-attractant. After
the chambers were incubated at 37 °C for 48 h, non-invaded cells on
the top of the transwell were scraped off with a cotton swab. Cells suc-
cessfully translocated were ﬁxed with 10% formalin, stained with 0.1%
crystal violet, and counted under a light microscope.
2.8. Microarray analysis
Total RNA from SW480-RNAa-MALAT1, SW480-RNAi-MALAT1, and
control SW480 cells was extracted using a Qiagen RNeasy kit (Qiagen,
USA). The Roche Human Genome NimbleGene Array GeneChips
(Roche, USA) were used for microarray analysis. Hybridization and
scanning of the genechips were performed by the KangCheng Biotech-
nology Company (ShangHai, China) according to the standard Roche
protocol. The data have been deposited in the public Gene Expression
Omnibus Repository (Accession number XXH100360/XXH1010128).
Signiﬁcance analysis of microarrays (SAM) was performed to identify
differentially expressed genes between SW480-RNAa-MALAT1 and
SW480-control, between SW480-RNAi-MALAT1 and SW480-control,
or between SW480-RNAa-MALAT1 and SW480-RNAi-MALAT1. Com-
mon differential genes were obtained by cross-comparing the three
data sets.
2.9. Functional analysis and gene annotation
The Molecule Annotation System (MAS, KangCheng, ShangHai,
China) was used to analyze GO and Pathways. The Database for Annota-
tion, Visualization, and Integrated Discovery was used to discover the
enriched function-related gene groups by gene-annotation enrichment
analysis (http://david.abcc.ncifcrf.gov/). The genes in the top ten clus-
ters (gene enrichment score N1) from the gene-annotation enrichment
analysis were selected.
2.10. In vivo functions assays
2 × 106 of SW480-RNAa-MALAT1, SW480-RNAi-MALAT1, or control
SW480 cells were injected subcutaneously in left and right ﬂank of 4- to
6-week-old Balb/C-nu/nu athymic nudemice (n=6per group) obtain-
ed from Animal Center of Southern Medical University. Tumor growth
was visualized and imaged using a whole-body GFP imaging system
(Lighttools, Encinitas, CA). Tumor size was measured by a slide caliper,
and tumor volume was calculated as follows: volume = (D × d2) / 2,
where D meant the longest diameter and d meant the shortest
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were diced into 1 mm3 cubes, and implanted into the mesentery at
the caecum terminus of the nude mice. Animal were kept until the
end of the experiment (8 weeks). The organs were ﬁxed with 10% neu-
tral buffered formalin and parafﬁn-embedded. Subsequently, consecu-
tive tissue sections were made for each block and stained with
hematoxylin–eosin (H&E) to observe the metastatic nodules in organs
under microscope. The experiments were performed according to insti-
tutional guidelines and approved by the Institution Animal Care andUse
Committee of Southern Medical University.
2.11. 2D electrophoresis proteomics analysis
SW620-scramble (SW620-Ctrl) and SW620-RNAa-MALAT1 cells
were collected and lysed. Protein concentrations were determined
using a modiﬁed Bradford assay (Ramagli 1999). The ﬁrst-dimensional
isoelectric focusing was carried out at 18 °C with a maximum current
setting of 50 mA/strip using conditions programmed in an IP Gphor
IEF unit (Amersham Biosciences). Second-dimension isoelectric focus-
ing was carried out at 10 °C with a maximum current setting of
400 mA in Ettan DIGE unit (Amersham Biosciences). The resulting gel
was then visualized by SYPRO Ruby staining. The image was scanned
at an excitation wavelength of 400 nM and an emission wavelength
of 630 nM. All images were captured on a Typhoon 9400 (Amersham
Biosciences). Quantiﬁcation of the protein expression and statisticalMALAT1
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Fig. 1.MALAT1 was up-regulated in human CRC tissues with metastasis. (A) Semi-quantitative
(T) than adjacent normal tissues (N). The highest level of MALAT1 was observed in CRCs wit
detected by real-time PCR and normalized to GAPDH. MALAT1 levels in all 9 groups (CRC, CR
the semi-quantitative analyses shown in A. *P b 0.05 compared to normal tissue group; **P b
with andwithoutmetastasis relative to match-normal tissues. The level of MALAT1 in human C
tastasis (nmCRC, n= 18).analysis were carried out using the Decyder-DIA software program
(Amersham Biosciences).
2.12. Protein MALDI-TOF/TOF analysis
Proteins were extracted from gel plugs and were puriﬁed using
Ziptip C18 (Millipore, USA). The eluted proteins were mixed with
MATRIX solution and spotted on MALDI plate using dry droplet meth-
od and analyzed using AbSciexTof/Tof instruments. Protein identi-
ﬁcation using peptide mass ﬁngerprinting (PMF) was performed
by the MASCOT search engine (http://www.matrixscience.com/)
(MatrixSicence Ltd., UK) against the MSDB protein database. Proteins
matching more than four peptides with a MASCOT score higher than
63 were considered signiﬁcant (P b 0.05). Carboamidomethylation of
cysteine was selected as the static modiﬁcation and oxidation of methi-
onine as the differential modiﬁcation. Protein identiﬁcationwas ﬁltered
with peak Erazor software.
2.13. Western blot analysis
Cells were washed twice with cold PBS and lysed in RIPA buffer (1×
PBS, 1% NP40, 0.1% SDS, 5 mM EDTA, 0.5% sodium deoxycholate, and
1 mM sodium orthovanadate) containing protease inhibitors. Whole
protein extracts were resolved on a 10% SDS polyacrylamide gel and
electrotransferred to polyvinylidene ﬂuoride membranes (Millipore,Sample 2
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0.05 compared to CRC and normal tissue group. (C) MALAT1 expression in human CRCs
RCswithmetastasis (mCRC, n=9)was signiﬁcantly higher than that in CRCswithoutme-
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saline (pH 7.5; 100 mM NaCl, 50 mM Tris, and 0.1% Tween-20) and
immunoblottedwith AKAP9 (Santa Cruz, USA) at 4 °C overnight follow-
ed by HRP (horseradish peroxidase)-labeled secondary antibody (Santa
Cruz) and detected by chemiluminescence. α-Tubulin expression was
used as a protein-loading control. The intensity of protein bands was
quantiﬁed with the Quantity One software (4.5.0 basic, Bio-Rad).
2.14. Immunoﬂuorescence
Cells plated on poly-L-lysine-coated glass coverslips were ﬁxed
with 4% paraformaldehyde, and washed with PBS. Cells were then
permeabilized with 0.1% Triton X-100/PBS for 10min and subsequently
incubatedwith primary antibodies followed by incubationwith ﬂuores-
cein isothiocyanate-tagged secondary antibodies. 4′,6-Diamidino-2-
phenylindole (DAPI)was used for the nuclear counterstain. The ﬂuores-
cence was recorded using an inverted ﬂuorescence microscope (Leica,
Germany).
2.15. Statistical analysis
The SPSS statistical software (Abbott Laboratories, USA)was used for
conducting all the statistical analyses. All results were conﬁrmed by
statisticians in the Department of Health Statistics, Southern Medical
University. The comparison between the two groups was analyzed by
Mann–Whitney U test. RT-PCR gray values, RT-qPCR assay, ﬂow cytom-
etry assay, plate clone formation assay, wound healing assay, and tumor
cell invasion assay were considered two-sided T tests. In vitro cell
growth assay was tested using factorial design ANOVA. For differentialSW
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Fig. 2. RNA activation-mediated overexpression of MALAT1 promoted CRC cell proliferation an
the transcription starting site of MALAT1 gene including CpG island, Ctrl (scramble control), P1
promoter region−348 bp), M1 (saRNA targeted inMALAT1mRNA+258 bp), M2 (saRNA targ
(saRNA targeted in MALAT1 mRNA +2584 bp). (B-C) saRNA-induced MALAT1 expression. S
MALAT1 expression were assessed by semi-quantitative analysis (B) and real-time PCR (C). GA
level of MALAT1 due to RNA activation (RNAa) as detected by semi-quantitative (D) and real-t
CCK-8 assay. (G) RNAa-activatedMALAT1 promoted CRC cell invasion as determined bymatrig
(Ctrl) (n= 3).expression of matched gels, protein spots whose intensities were either
increased or decreased two-folds or more were marked and then con-
ﬁrmed bymanual inspection of all relevant 2-D gel to ensure consisten-
cy. In all samples, P b 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. MALAT1 was upregulated in metastatic CRC cells and human primary
CRC tissues with lymph node metastasis
The expression of MALAT1 was examined in nine CRC cell lines, 18
human CRC tissues paired with adjacent non-neoplastic normal tissues
and additional nine carcinoma tissues with lymphoma metastasis. We
found that MALAT1 expression was higher in COLO-205, Lovo, SW620,
M5 cells that originate frommetastatic CRC comparedwith cells derived
from primary CRC including HT29, HCT116, SW480, LS174t, and CaCo-2
(Supplemental Figure S1A–B). Importantly, MALAT1 expression level in
tumorswas signiﬁcantly higher than those in the corresponding normal
tissues (Supplemental Figure S1C–D). Moreover MALAT1 expression
was consistently increased even more in CRC tissues with lymph node
metastases (Fig. 1), suggesting thatMALAT1maybe involved in colorec-
tal cancer metastasis.
3.2. RNA activation (RNAa)-mediated overexpression of MALAT1 promoted
CRC cell proliferation and migration/invasion
RNAa is a newly identiﬁedmechanism for gene induction and is trig-
gered by small activating RNA (saRNAs). saRNA interaction with pro-
moter and GC rich region of mRNAs triggers expression of endogenous0.6
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170 M.-H. Yang et al. / Biochimica et Biophysica Acta 1852 (2015) 166–174genes. We designed six speciﬁc saRNAs targeting either the promoter
or GC rich regions of MALAT1 gene (Fig. 2A). The saRNAs or negative
control RNA were individually transfected into SW480 cells, and
the MALAT1 expression was detected by semi-quantitative PCR
and qPCR. Compared to the negative control, most of the saRNAs upreg-
ulated MALAT1 levels by 1.5 to 3.5 fold (Fig. 2B and C). saRNA-348 bp
(P2) appeared to be an optimal activator of MALAT1 expression (3.5-
fold increase). Therefore, this activator was selected for subsequent
experiments.
To determine the role of MALAT1 in CRC tumourigenesis and
progression, SW480 and SW620 cells were transfected with saRNA-
348 bp (MALAT1-RNAa or RNAa) and control RNA, respectively. As
shown in Fig. 2D and E, MALAT1 transcript was robustly induced in
both SW480 and SW620 cells, which increased the proliferation of
both cancer cells (Fig. 2F). The role of MALAT1 in CRC proliferation
was conﬁrmedby usingRNAi-mediated blockage ofMALAT1expression
(Supplemental Figure S2). The ability of MALAT1-RNAa cells to form
colonies was also much higher than those transfected with control
RNA (Supplemental Figure S3A). Cell cycle analysis with ﬂow cytometry
revealed that MALAT1 caused a signiﬁcant decrease of cells in G1/G0
phase with an increase of cells in S phase (Supplemental Figure S3B).
To determine if RNAa-mediated expression of MALAT1 affects CRC
migration and invasion, we performed wound-healing and matrigel
invasion assay using SW480 and SW620 cells. Over-expression of
MALAT1 caused a signiﬁcant increase in CRC cell migration (Supple-
mental Figure S4A) and invasion (Fig. 2G). On the contrary, migration
and invasive capacity of the CRC cells were markedly decreased when
MALAT1 was blocked by siRNA (Supplemental Figure S4B–C). These
data demonstrate that endogenous activation of MALAT1 promoted
CRC cell proliferation and invasion.H&E
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in vivo.3.3. MALAT1 promoted CRC tumor growth and metastasis in vivo
To assess the effect of MALAT1 on CRC tumor growth in vivo, we
injected MALAT1-activated SW480 cells, MALAT1-depleting SW480
cells, and their control SW480 cells (with scramble saRNA or control
shRNA) subcutaneously into nude mice respectively, and monitored
the growth of the resultant primary tumors. As shown in Fig. 3A, the xe-
nograft tumors developed at the injection site after 15 days. During the
4 weeks of observation period, the tumor growth in the MALAT1-RNAa
group was signiﬁcantly faster than that in the control groups. Conse-
quently, the tumor volumes of the MALAT1-RNAa group were signiﬁ-
cantly larger than those of control groups. Immunohistochemistry
staining demonstrated that the tumors of MALAT1-activated group
displayed a much higher Ki-67 index than the control group (Fig. 3B).
On the other hand, tumor growth, tumor volume and Ki67 expression
in the MALAT1-blocked group were signiﬁcantly attenuated compared
to the controls (Fig. 3C–D). These data demonstrate that MALAT1
plays a crucial role in CRC growth in vivo.
In order to determine the effect of MALAT1 onmetastasis of CRC, we
performed surgical orthotopic implantation of CRC tumor cubes that
were grown from SW480 cells. The tumors from control, MALAT1-
activated, or MALAT1-blocked SW480 cells were implanted into
mouse caecum terminus. After 8 weeks, MALAT1-RNAa cells exhibited
a dramatic increase in the metastasis in colon, lung, and liver as com-
pared to the controls (Fig. 4A). Conversely, the tumor invasion in intes-
tinal wall and metastasis to liver and lung of the MALAT1-blocked
tumor were diminished (Fig. 4A). Histological analysis showed an
increased invasion of tumor cells in intestinal wall and metastasis
in liver and lungwith theMALAT1-activated tumor compared to control
tumor while no tumor was observed in these tissues with the MALAT1-H&E
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171M.-H. Yang et al. / Biochimica et Biophysica Acta 1852 (2015) 166–174blocked tumor (Fig. 4B). Quantitative analysis revealed that RNAa-
MALAT1 signiﬁcantly promoted while knockdown of MALAT1 blocked
the metastasis (Fig. 4C).
Collectively, these results demonstrated that MALAT1 promotes
tumor growth and metastasis in vivo.
3.4. Identiﬁcation of MALAT1 targets by proteomic and cDNA microarray
analyses
To identify the downstream targets mediating MALAT1 function in
CRC tumor growth and metastasis, we performed proteomic analysis
using 2D gel electrophoresis (Supplemental Figure S5A). Compared
with cells without MALAT1 induction (Scramble saRNA), three proteins
were signiﬁcantly up-regulated in MALAT1-activated cells including
AKAP-9, peptidyl-prolyl cis-tRNAs isomerase A, PPLase1), and glial
ﬁbrillary acidic protein (GFAP1). Meanwhile, coiled-coil domain-
containing protein 155 (KASH5), Ras-related protein Rab-3A (Rab3A),
and GTP-binding nuclear protein RNA (Ran) were down-regulated
(Supplemental Figure S5B).
To explore the potential mechanism underlying MALAT1-mediated
invasion and metastasis of CRC cells and to further screen MALAT1-
dependent genes, we performed cDNA array analysis of SW480 cells
with altered MALAT1 expression using Roche HumanGene chips (Sup-
plemental Figure S6A). Compared with control cells, 396 genes were
up-regulated while 458 genes down-regulated in RNAa-MALAT1 cells
(Figure S6B). In MALAT1-depleted cell (RNAi-MALAT1), 422 genes
were up-regulated while 518 genes down-regulated (Figure S6B).
Paired-comparison revealed that the expression of 243 genes was
depended on MALAT1 in SW480 cells. The molecule annotation system
(MAS) and the DAVID gene-annotation enrichment analysis (gene
enrichment score N1) revealed that the 243 target genes are involved
in cell differentiation, cell cycle, cytoskeleton, and macromoleculemetabolic process. By comparing the 243 genes frommicroarray analy-
sis with the 6 genes identiﬁed by proteomic analysis, we found that
AKAP-9 was the only gene that was detected by both approaches
(Supplemental Figure S6C and Figure S7), suggesting that AKAP-9 may
be related to MALAT1-dependent CRC tumorigenesis. To validate the
role of MALAT1 in AKAP-9 expression, we activated or knocked down
MALAT1 in SW480 cells and detected AKAP-9 protein expression. As
shown in Supplemental Figure S8A, AKAP9 protein was up-regulated
in MALAT1-activated SW480 cells but attenuated in MALAT1-blocked
cells. The protein expression was also conﬁrmed by immunostaining
(Figure S8B).
3.5. AKAP-9 was expressed in CRC cells and tumors
In order to determine if AKAP-9 mediates MALAT1 function in CRC
cell proliferation and migration/invasion, we ﬁrst detected AKAP-9 ex-
pression in CRC cells and tumor tissues. As shown in Fig. 5A–B, AKAP-
9 expression was higher in M5, Lovo, and SW620 cells originating
from metastatic CRC compared with cells derived from primary CRC
included SW480, HCT116, and DLD1, consistent with the MALAT1 ex-
pression (Supplemental Figure S1A–B). Importantly, AKAP-9 expression
in tumors was signiﬁcantly elevated compared to the corresponding
normal tissues in nine human CRC tumors (Fig. 5C–E). These results
suggested that AKAP-9 may be involved in the colorectal cancer
development.
3.6. AKAP-9 was essential for MALAT1-mediated CRC proliferation,
migration and invasion
To test ifMALAT1-mediated phenotype in CRCwas indeed due to the
induction of its target gene AKAP-9, we knocked down AKAP-9 by
shRNA and tested if MALAT1-mediated CRC proliferation, migration,
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Fig. 5. AKAP-9 expressed in CRC cells and tumor tissues. (A) AKAP-9 protein expression in six CRC cell lines was detected by western blot and normalized to α-tubulin expression.
(B) AKAP-9 expression in six CRC cell lines was examined by immunocytochemistry staining. (C) AKAP-9 expression was detected in nine human CRC tumor tissues. AKAP-9 levels in
CRC tumor (T) were signiﬁcantly higher than adjacent normal tissues (N) as detected by western blot. (D) Quantitative analysis of AKAP-9 expression shown in C by normalizing to α-
tubulin. **P b 0.001 compared to normal tissue (Norm), n= 9. (E) AKAP-9 expression in CRC tumor tissue was detected by immunohistochemistry staining.
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AKAP-9 shRNA effectively blocked AKAP-9 expression that was induced
by MALAT1 activation in SW480 cells. Silencing of AKAP9 inhibited
MALAT1-induced proliferation (Fig. 6B), migration (Fig. 6C) and inva-
sion (Fig. 6D) of SW480 CRC cells. These results demonstrate that
MALAT1 promoted the proliferation, migration, and invasion of CRC
through AKAP-9.
4. Discussion
Although the regulation of CRC growth is well understood, the
mechanism governing CRC proliferation, migration, invasion or metas-
tasis remains largely unknown. Our study demonstrates that MALAT1
is a novel pro-metastatic factor for CRC. Induction ofMALAT1 in primary
CRC strongly enhanced the tumor growth and metastasis in mice,
underscoring the essential role of MALAT1 in CRC metastasis.
Because MALAT1 is a long (8 kb) gene, traditional expression clone
vector is difﬁcult to be efﬁciently transfected into cells. Thus, most of
the previous functional studies are limited to the knockdown approach
[22]. RNA activation-induced gene expression by targeting promoter
sequence allowed us to physiologically and directly test the function
of a given gene [23–26]. In fact, lentiviral-based delivery of dsRNAs
has been reported to activate VEGF expression by targeting promoter
sequences in an ischemic mouse model [27]. We found for the ﬁrst
time that RNA activation can up-regulate MALAT1 expression in CRC
cells.MALAT1overexpression via RNA activation signiﬁcantly promoted
CRC cell growth and colony formation, cell cycle G1/S transition in vitro,and the tumorigenesis of CRC xenograft in vivo. By using RNA activation,
wewere able to demonstrate thatMALAT1 promotes colorectal carcino-
ma metastasis. MALAT1 expression level in CRC tissues of human pa-
tients with lymph node metastasis was higher than those without
metastasis. Clinic pathological analysis also found that high-level of
MALAT1 was associated with lymph node metastasis or distant metas-
tasis. In animal models, increased expression of MALAT1 was sufﬁcient
to promote CRC metastasis to lung, liver and organs in the peritoneal
cavity. This correlation indicates that MALAT1 may play a causal role
in colorectal cancer metastasis, consistent with a recent study showing
that MALAT1 is a potentially active player in the metastatic process of
lung adenocarcinoma. MALAT1 promotes cell motility of lung cancer
cells through transcriptional or post-transcriptional regulation of
motility-related genes.
AlthoughMALAT1 is involved inmetastasis of different cancers, little
is known about the underlying molecular mechanism. To begin to ex-
plore how MALAT1 regulates tumor invasion and metastasis in CRC,
high-throughput gene array and proteomic techniques have identiﬁed
AKAP-9 as the only gene that was induced in MALAT1-activated CRC
cells. AKAP9 is linked to cancer development or metastasis including
oral cancer [28], melanomas [29], thyroid carcinomas [30,31], breast
cancer [32], and lung cancer [33]. However, the function of AKAP-9 in
the onset of these tumors has not been experimentally established.
There is also no data describing the role of AKAP-9 in the development
of CRC cancer. Our results suggest that AKAP-9 is associated with
MALAT1 in CRC tumor growth, consistent with a number of microarray
dataset showing that AKAP-9 is correlated with MALAT1 in human CRC
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173M.-H. Yang et al. / Biochimica et Biophysica Acta 1852 (2015) 166–174tissues, primarily cultured CRC, or CRC cell lines (http://www.ncbi.nlm.
nih.gov/geoproﬁles/advanced). In fact, AKAP-9 is critical for MALAT1-
mediated CRC cell activities. Knockdown of AKAP-9 signiﬁcantly
attenuatedMALAT1 function in CRC cell proliferation, migration and in-
vasion, suggesting that MALAT1 promotes the proliferation and migra-
tion/invasion of CRC cells through targeting AKAP-9. In view of the
important role of migration and invasion in metastasis, AKAP-9 is likely
to be critical for MALAT1-mediated CRC metastasis, which would be
an interesting and important subject for future investigation. An-
other question remaining to be explored is how AKAP-9 mediates
MALAT1 function in CRC tumor growth. Despite of these limitations,
this study has provided novel insight about CRC tumor development
and metastasis.Funding
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